GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
A phase 3 trial of GM1 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer is a phase 3 interventional study registered as NCT06994507 by Qilu Pharmaceutical Co., Ltd., with 352 participants planned, started 2025-08-01 and due to reach its primary completion in 2026-09. Interventions recorded: GM1 and Placebo.
Similar pages
not linked directly; found by shared links- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.